Press releases

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand therapy platform  across multiple aggressive solid tumors, hereby publishes the Annual Report 2025. The report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS), a clinical-stage radiopharmaceutical company pioneering a first-in-class uPAR-targeted radioligand therapy platform  addressing multiple aggressive solid tumors, hereby publishes the Year-end report Q4 2025. The Year-end report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

COPENHAGEN, Denmark, February 17, 2026 - Curasight A/S (TICKER:CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies across multiple aggressive solid tumors, will present recent company progress including the ongoing Phase 1 clinical trial uTREAT® in glioblastoma, at the TD Cowen 46[th] Annual Health Care Conference on Tuesday, March 3[rd], 2026, at 11:50 a.m. Eastern Time / 5:50 p.m. CET in Boston.

Copenhagen, 9 February 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the company has received notification that Pentwater Capital Management LP, 1001 10th Avenue South, Naples, FL 34102, on 3. February 2026 has reduced its holding of shares in the Company.

· Clear uptake of uTREAT® in aggressive brain cancer (glioblastoma)
· Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and more targeted treatment of high-grade gliomas and other uPAR expressing aggressive solid tumors
 

Copenhagen, 12[th] January, 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen activator receptor), the functional driver of invasion, angiogenesis, and metastasis across most solid tumors, today announced encouraging preliminary data from the first patient dosed in ongoing Phase 1 clinical trial in patients with high-grade gliomas.

Copenhagen, 5 January 2026 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain types of cancers, announced that CEO Ulrich Krasilnikoff and CMO prof. Andreas Kjær will be in San Francisco during the 44[th] J.P. Morgan Healthcare Conference being held January 12-15, 2026.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has, as previously communicated on 12 December 2025, entered into a loan agreement with Fenja Capital II A/S ("Fenja Capital", the "Lender") regarding a loan facility. Today, the Board of Directors resolved to issue a convertible loan note to Fenja Capital based on the authorization granted by the Extraordinary General Meeting held earlier today

Copenhagen, 29 December 2025 – Curasight A/S (“Curasight” or the “Company” – TICKER: CURAS) today held its Extraordinary General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark 

· Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT® belonging to Curasight’s treatment platform
· No patient safety issues were reported
· The dosing marks a key milestone with Curasight now in clinical development with both its therapeutic (uTREAT®) and diagnostic (uTRACE®) platforms

Copenhagen, 18 December 2025 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) today announced the successful and safe dosing of the first patient in the Phase 1 trial using uTREAT in brain cancer (high grade gliomas). The news marks the initiation of the first clinical trial under the company’s therapeutic platform uTREAT, investigating it as a potential treatment option for glioblastoma.

The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company”) to an Extraordinary General Meeting on

29 December 2025 at 10:00 AM (CET) at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark.